ATE514714T1 - Hutnfr1-selektive antagonisten - Google Patents
Hutnfr1-selektive antagonistenInfo
- Publication number
- ATE514714T1 ATE514714T1 AT07005603T AT07005603T ATE514714T1 AT E514714 T1 ATE514714 T1 AT E514714T1 AT 07005603 T AT07005603 T AT 07005603T AT 07005603 T AT07005603 T AT 07005603T AT E514714 T1 ATE514714 T1 AT E514714T1
- Authority
- AT
- Austria
- Prior art keywords
- hutnfr1
- ligand
- amino acid
- acid sequences
- selective antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07005603A EP1972637B1 (de) | 2007-03-19 | 2007-03-19 | huTNFR1-selektive Antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE514714T1 true ATE514714T1 (de) | 2011-07-15 |
Family
ID=38358021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07005603T ATE514714T1 (de) | 2007-03-19 | 2007-03-19 | Hutnfr1-selektive antagonisten |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8404238B2 (de) |
| EP (2) | EP1972637B1 (de) |
| JP (1) | JP5534819B2 (de) |
| CN (1) | CN101679520B (de) |
| AT (1) | ATE514714T1 (de) |
| CA (1) | CA2680085C (de) |
| ES (1) | ES2368764T3 (de) |
| PL (1) | PL1972637T3 (de) |
| WO (1) | WO2008113515A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2368764T3 (es) | 2007-03-19 | 2011-11-22 | Universität Stuttgart | ANTAGONISTAS SELECTIVOS DE huTNFR1. |
| CN103249742B (zh) * | 2010-09-16 | 2017-04-12 | 巴利奥医药股份公司 | 抗人肿瘤坏死因子1型受体抗体 |
| ES2378976B1 (es) * | 2010-09-21 | 2013-05-06 | Fundación Centro Nacional De Investigaciones Oncológicas (Cnio) | Anticuerpo contra ephrin b2 y su uso. |
| CA2817015A1 (en) | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
| EP2748197A2 (de) | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Fc-bispezifische tandem-antikörper |
| TW201444872A (zh) | 2013-03-06 | 2014-12-01 | Merrimack Pharmaceuticals Inc | 抗C-MET串聯Fc雙特異性抗體 |
| CA3019692A1 (en) * | 2016-04-05 | 2017-10-12 | Universitat Stuttgart | Monovalent inhibitor of hutnfr1 interaction |
| GB201617622D0 (en) * | 2016-10-18 | 2016-11-30 | VIB VZW and Universiteit Gent | Means and methods to treat inflammation |
| EA202091182A1 (ru) * | 2017-11-27 | 2020-07-29 | Балиофарм Аг | АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА |
| WO2019246313A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| EP3927828A4 (de) | 2019-02-21 | 2023-02-01 | Enosi Life Sciences Corp. | Antikörper und enonomere |
| CN116406381A (zh) * | 2020-05-19 | 2023-07-07 | 希望之城 | 工程化抗前列腺干细胞抗原融合蛋白及其用途 |
| WO2022033483A1 (zh) * | 2020-08-10 | 2022-02-17 | 佧珐药业有限公司 | 多功能的免疫效应细胞及其应用 |
| WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4006269A1 (de) * | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antikoerper gegen den tumor-nekrosefaktor-rezeptor |
| US20080008713A1 (en) * | 2002-06-28 | 2008-01-10 | Domantis Limited | Single domain antibodies against tnfr1 and methods of use therefor |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| ES2368764T3 (es) | 2007-03-19 | 2011-11-22 | Universität Stuttgart | ANTAGONISTAS SELECTIVOS DE huTNFR1. |
-
2007
- 2007-03-19 ES ES07005603T patent/ES2368764T3/es active Active
- 2007-03-19 PL PL07005603T patent/PL1972637T3/pl unknown
- 2007-03-19 EP EP07005603A patent/EP1972637B1/de active Active
- 2007-03-19 AT AT07005603T patent/ATE514714T1/de active
-
2008
- 2008-03-13 EP EP08716529A patent/EP2121759A2/de not_active Ceased
- 2008-03-13 US US12/531,000 patent/US8404238B2/en active Active
- 2008-03-13 WO PCT/EP2008/002033 patent/WO2008113515A2/en not_active Ceased
- 2008-03-13 CA CA2680085A patent/CA2680085C/en active Active
- 2008-03-13 CN CN200880009245.3A patent/CN101679520B/zh active Active
- 2008-03-13 JP JP2009553952A patent/JP5534819B2/ja active Active
-
2013
- 2013-02-13 US US13/765,923 patent/US9045535B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101679520B (zh) | 2014-01-15 |
| WO2008113515A2 (en) | 2008-09-25 |
| WO2008113515A3 (en) | 2008-11-13 |
| JP2010521508A (ja) | 2010-06-24 |
| EP1972637A1 (de) | 2008-09-24 |
| US8404238B2 (en) | 2013-03-26 |
| US20130244341A1 (en) | 2013-09-19 |
| US20100150916A1 (en) | 2010-06-17 |
| EP2121759A2 (de) | 2009-11-25 |
| ES2368764T3 (es) | 2011-11-22 |
| JP5534819B2 (ja) | 2014-07-02 |
| CA2680085C (en) | 2016-05-17 |
| EP1972637B1 (de) | 2011-06-29 |
| CA2680085A1 (en) | 2008-09-25 |
| CN101679520A (zh) | 2010-03-24 |
| US9045535B2 (en) | 2015-06-02 |
| PL1972637T3 (pl) | 2012-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE514714T1 (de) | Hutnfr1-selektive antagonisten | |
| JOP20190083A1 (ar) | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها | |
| MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| WO2009095489A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
| ATE509953T1 (de) | Antikörper gegen den erythropoietinrezeptor und verwendungen davon | |
| EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
| NO345046B1 (no) | Oral doseringsform | |
| LT3339445T (lt) | Baltymai, suryšantys interleukiną 13 | |
| EA200970810A1 (ru) | Модифицированные полипептиды рецептора активина и их применение | |
| WO2009009173A3 (en) | Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases | |
| CY1110980T1 (el) | Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες | |
| WO2007016538A3 (en) | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | |
| EP1983002A3 (de) | Tyrosinphosphorylations-Stellen und spezifische Antikörper | |
| WO2008013948A3 (en) | Tyrosine phosphorylation sites | |
| EA200600735A1 (ru) | Нуклеиновые кислоты, специфично связывающие биоактивный грелин | |
| WO2009071689A3 (de) | 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| WO2008054597A3 (en) | Tyrosine phosphorylation sites | |
| WO2006113681A3 (en) | Plant-derived elastin binding protein ligands and methods of using the same | |
| WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors | |
| WO2008013934A8 (en) | Tyrosine phosphorylation sites | |
| EP1983003A3 (de) | Tyrosinphosphorylationsstellen und spezifische Antikörper | |
| DE602005019416D1 (de) | Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid | |
| WO2010040736A3 (en) | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling | |
| WO2008036337A8 (en) | Predicted phosphorylation sites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1972637 Country of ref document: EP |